Working and treatment of Benserazide - Prolopa Prescription drug
|
|
|
|
|
|
| Working and treatment of
Benserazide - Prolopa |
Benserazide - Prolopa is a DOPA decarboxylase inhibitor, which is
unable to cross the blood-brain barrier. A combination with L-DOPA
used as Co-Beneldopa used in the treatment of Parkinson's disease.
Serazide or Ro 4-4602 is another name for benserazide known to the
medical world. Restless Legs Syndrome uses the similar combination
for its treatment. Levodopa is a dopamine (L-DOP precursor, which
administers to increase levels of dopamine in the Central Nervous
System. Most levodopa is decarboxylated to dopamine before it
reaches the brain.
Benserazide - Prolopa is a DOPA decarboxylase inhibitor, which is
unable to cross the blood-brain barrier. This makes dopamine unable
to cross the blood-brain barrier keeping the body expose to adverse
effects. Tests show less dopamine is available to the Central
Nervous System and excess dopamine circulated in cerebral tissues
causing major adverse effects. They provide better impulse to the
body in preventing from series of strokes. It inhibits the
decarboxylation allowing the levodopa to enter into the brain on
consumption of benserazide. Benserazide - Prolopa does not enter the
CNS; DOPA decarboxylase is uninhibited there and metabolizes the
levadopa into useful dopamine.
Benserazide has a little therapeutic effect on its own and only
administered in combination with levodopa. Thus, Benserazide -
Prolopa helps in excess secretion of levodopa in the body converting
to dopamine. These directly control the action of the cerebrum in
sending body impulses. Doctors and physicians prescribe them for
their effective action in any human body. In UK and Canada, they
have brand names Madopar and Prolopa respectively both made by
Roche. US have not approved the use of benserazide, where carbidopa
used for the same purpose.
|
|
|
|
|
